Business Wire

NY-CLARITY-AI

17.3.2022 18:06:12 CET | Business Wire | Press release

Share
Clarity AI: Only 7% of a Sample of 31,000 Equity Funds Have More Than 10% “Green Revenues,” as Defined in the EU Taxonomy

The EU Taxonomy aims to align all market stakeholders on what is considered sustainable in the context of the EU, but investors need greater transparency on just how green the funds they are buying really are. Analysis by Clarity AI, the market-leading, global sustainability technology platform, reveals significant differences between fund revenues aligned with green – and EU Taxonomy related – objectives across different types of sustainable investment products in the market today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005718/en/

Under the Sustainability Finance Disclosure Regulation (or SFDR), investors need to report the EU Taxonomy alignment as part of the sustainability profile of funds, which need to be classified into one of three categories:

  • Article 6: non-sustainable funds
  • Article 8: funds that promote sustainable characteristics but not as an overarching objective
  • Article 9: funds that have been specifically created to address sustainability goals

In a whitepaper titled “EU Taxonomy: Using Tech to Analyze ‘Green’ Fund Performance,” Clarity AI analyzed an investable universe of 31,000 equity funds on how these products perform against new EU Taxonomy requirements and assessed the common traits across funds, which are often branded in some way as “green.” The analysis shows that:

  • Globally, 3.6% of revenues can be considered green (“green revenues”) – that is, they contribute to mitigating climate change.
  • Only 7% of the 31,000 equity funds analyzed have more than 10% green revenues, as defined in the EU taxonomy.1
  • Article 9 climate-branded funds present four times higher alignment with the EU taxonomy than the overall sample average, with 15% of revenues classified as green. Article 8 funds, however, have a similar alignment to the average, with 3.9% green revenues.
  • Funds focused on sectors that are doing heavy lifting in the green transition, such as utilities, show a higher exposure and alignment, with 25% green revenues.
  • Funds with equity themes, such as alternative energy, are naturally more aligned with a green economy, with up to 27% green revenues.

Patricia Pina, Head of Product Research & Innovation at Clarity AI, said: “Considering the disparate definitions of and frameworks for sustainability all around the world, we can look to the EU Taxonomy as a pioneer in setting a common standard to align a large segment of global market stakeholders. At Clarity AI, we believe regulation needs to be supported by detailed, data-led insights, and transparency cannot be a nice-to-have. It is a must-have.

“The EU recognizes that a key requirement to further the development of the sustainable investment market is ‘access to high-quality sustainability-related data.’ 2 This high-quality data also means moving away from subjectivity and using an objective and fact-based definition of what should be considered ‘green,’ ‘social,’ ‘environmental,’ and so on. The EU taxonomy gives us a common language that will enable stronger decision making and an acceleration to a more sustainable economy.

“Reliable, transparent insights are at the heart of fact-based sustainable finance. They should become the norm in making informed decisions around ‘green’ investing.”

Notes to editors

About Clarity AI

Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors and organizations. As of December 2021, Clarity AI’s platform analyzes more than 30,000 companies, 180,000 funds, 198 countries and 187 local governments, and delivers data and analytics for investing, corporate research and reporting. Clarity AI has offices in the US, Europe, and the Middle East. Clarity AI’s client network manages trillions in assets under management. clarity.ai

Methodology

Clarity AI developed a comprehensive assessment of how companies and funds align with the EU Taxonomy classification of sustainability using its proprietary sustainable analytics technology platform. Clarity AI draws on the broadest possible spectrum of tools and data sources available to increase the coverage, precision and objectivity of the sustainability analysis, while remaining transparent. The method in this paper relies on the three steps of Clarity AI's EU Taxonomy analysis and displays two key metrics that investors will need to report:

  • % Eligible green revenue: as defined by revenues exposed to the activities outlined in the EU Taxonomy
  • % Aligned green revenue: which builds upon eligible activities and embeds an assessment of the technical screening criteria, DNSH and SS requirements

Through its sustainability tech platform, Clarity AI can scalably assess >180,000 funds and >30,000 organizations. For this report, Clarity AI selected a subset of its universe where it takes a deeper look into the EU Taxonomy alignment for more than 31,000 funds globally. Clarity AI focused the analysis on the parent funds (independent of the asset classes) of equity-only funds for which it has enough characterization of the fund (e.g., assets under management, description, etc.). For the sake of comparison, they cover a broad range of regions, sectors and strategies.

1 As per the EU Taxonomy’s methodology of calculating alignment: Use the weighted average of the percent green revenues by company, which is based on the weights within a portfolio

2 As per the European Commission study published in June 2021

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye